Back to top
more

Novo Nordisk (NVO)

(Delayed Data from NYSE)

$131.54 USD

131.54
4,315,513

+1.55 (1.19%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $131.58 +0.04 (0.03%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 28% (181 out of 250)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Novo Nordisk (NVO) Rises Higher Than Market: Key Facts

by Zacks Equity Research

In the closing of the recent trading day, Novo Nordisk (NVO) stood at $144.49, denoting a +0.57% change from the preceding trading day.

Novo Nordisk's (NVO) Hypertension Drug Study Fails to Meet Goal

by Zacks Equity Research

Novo Nordisk (NVO) declines as a late-stage study of its uncontrolled hypertension and advanced chronic kidney disease candidate, ocedurenone, fails to achieve the primary goal.

La-Z-Boy and Winnebago have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

La-Z-Boy and Winnebago have been highlighted as Zacks Bull and Bear of the Day.

Novo Nordisk (NVO) to Invest $4.1B in Clayton Facility Expansion

by Zacks Equity Research

Novo Nordisk (NVO) plans to invest $4.1 billion in order to expand its Clayton facility with a second manufacturing plant, boosting capacity for injectable treatments and creating 1,000 new jobs.

Why Novo Nordisk (NVO) is a Top Stock for the Long-Term

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Kinjel Shah headshot

Is Eli Lilly (LLY) a Buy on Tirzepatide Success in Sleep Apnea?

by Kinjel Shah

Eli Lilly (LLY) files for the approval of tirzepatide to treat obstructive sleep apnea in adults with obesity in the United States. If approved, sales of the blockbuster drug will rise further.

Investors Heavily Search Novo Nordisk A/S (NVO): Here is What You Need to Know

by Zacks Equity Research

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Novo Nordisk (NVO) Gains As Market Dips: What You Should Know

by Zacks Equity Research

In the most recent trading session, Novo Nordisk (NVO) closed at $140.99, indicating a +0.13% shift from the previous trading day.

Kinjel Shah headshot

Here's Why Eli Lilly (LLY) is Probably the Best Drug Stock Now

by Kinjel Shah

Eli Lilly (LLY) enjoys strong fundamentals and is expected to consistently do well, mainly supported by its new drugs and its solid pipeline.

Brokers Suggest Investing in Novo Nordisk (NVO): Read This Before Placing a Bet

by Zacks Equity Research

According to the average brokerage recommendation (ABR), one should invest in Novo Nordisk (NVO). It is debatable whether this highly sought-after metric is effective because Wall Street analysts' recommendations tend to be overly optimistic. Would it be worth investing in the stock?

Santanu Roy headshot

Take the Zacks Approach to Beat the Markets: Snap, Naspers, e.l.f. Beauty in Focus

by Santanu Roy

Last week, our time-tested methodologies served investors well in navigating the market. Check out some of our achievements from the past three months.

Novo Nordisk (NVO) Advances While Market Declines: Some Information for Investors

by Zacks Equity Research

Novo Nordisk (NVO) closed the most recent trading day at $142.50, moving +0.01% from the previous trading session.

Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch

by Zacks Equity Research

Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.

Sanghamitra Saha headshot

Best ETF Areas of Last Week

by Sanghamitra Saha

Wall Street was upbeat last week.

Structure Therapeutics (GPCR) Rallying on Obesity Drug Data

by Zacks Equity Research

Structure Therapeutics (GPCR) stock sees an upside on positive top-line data from a phase IIa obesity study as well as a capsule-to-tablet PK study on its obesity candidate, GSBR-1290.

Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Macy's and Five Below have been highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Macy's and Five Below have been highlighted as Zacks Bull and Bear of the Day

Here is What to Know Beyond Why Novo Nordisk A/S (NVO) is a Trending Stock

by Zacks Equity Research

Recently, Zacks.com users have been paying close attention to Novo Nordisk (NVO). This makes it worthwhile to examine what the stock has in store.

The Zacks Analyst Blog Highlights Stocks recently featured in the blog include: Novo Nordisk, TotalEnergies, U.S. Bancorp and Flanigan's

by Zacks Equity Research

Novo Nordisk, TotalEnergies, U.S. Bancorp and Flanigan's are included in this Analyst Blog.

Sheraz Mian headshot

Top Analyst Reports for Novo Nordisk, TotalEnergies & U.S. Bancorp

by Sheraz Mian

Today's Research Daily features new research reports on 16 major stocks, including Novo Nordisk A/S (NVO), TotalEnergies SE (TTE) and U.S. Bancorp (USB), as well as a micro-cap stock Flanigan's Enterprises, Inc. (BDL).

Tirthankar Chakraborty headshot

ECB Rate Cut Propels European Markets: 3 Must-Watch Stocks

by Tirthankar Chakraborty

Historic ECB rate cut bolstered European stocks, which calls for keeping a tab on Siemens (SIEGY), ASML Holding (ASML) and Novo Nordisk (NVO) for solid growth.

New to Investing? This 1 Medical Stock Could Be the Perfect Starting Point

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Focus List.

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

by Zacks Equity Research

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Is Trending Stock Novo Nordisk A/S (NVO) a Buy Now?

by Zacks Equity Research

Zacks.com users have recently been watching Novo Nordisk (NVO) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Abhinab Dasgupta headshot

Beat the Market the Zacks Way: EverQuote, Micron, Amgen in Focus

by Abhinab Dasgupta

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.